Search Results for "Brilinta Sales"

13:31 EDT 30th March 2015 | BioPortfolio

Matching Channels

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...

Sales Jobs

Pfizer

Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have ...

Boehringer Ingelheim

Boehringer Ingelheim is a global pharmaceutical company with annual sales of over $16 billion, making it the 10th largest pharmaceutical company in the world based on sales.  With bases in 47 c...

Plavix

Plavix is a clot-busting drug, produced by Bristol-Myers Squibb Company, and reached annual sales in 2009 of $4.2m, making the third highest drug in the world (based on 2009 annual sales). Prescri...

Matching News

Mixed results for AstraZeneca in high-profile Brilinta study

Experts say AstraZeneca is at risk of ‘diminishing returns’ in the clinical advantages of its blood-thinning drug Brilinta, after it showed mixed results in a post heart attack trial. A large outc...

AstraZeneca’s troubled Brilinta gets welcome lift

AstraZeneca has reported positive primary endpoint results for its anti-clogging drug Brilinta to treat patients who have had a heart attack or severe chest pains. Clinical trials involving over 21,00...

AZ unveils Brilinta data, seeks label extension

AstraZeneca plc (LSE:AZN; NYSE:AZN) revealed new details from a 21,000-patient CV outcomes study showing that long-term use of the anticoagulant Brilinta ticagrelor reduced the incidence of major thro...

ACC 2015: AstraZeneca optimistic on Brilinta after PEGASUS, others less so

AstraZeneca's US president Paul Hudson is optimistic about the opportunities for Brilinta (ticagrelor) in longer-term treatment of acute coronary syndrome (ACS) based on results from the Phase III PEG...

AstraZeneca developing reversal agent for blood-thinner Brilinta

LONDON, Nov 13 (Reuters) - AstraZeneca is developing an antibody treatment to rapidly reverse the blood-thinning effects of its heart drug Brilinta in rare emergency situations, such as urgent surgery...

AstraZeneca study of Brilinta meets primary endpoint

Anglo-Swedish drug major AstraZeneca has announced its PEGASUS-TIMI 54 study of Brilinta (ticagrelor) has met its primary endpoint.

AstraZeneca begins development programme for BRILINTA reversal agent

AstraZeneca has begun a pre-clinical development programme to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor (BR...

AstraZeneca developing reversal agent for heart drug Brilinta

LONDON (Reuters) - AstraZeneca is developing an antibody treatment to reverse the blood-thinning effect of its heart drug Brilinta in rare emergency situations, such as urgent surgery or in the event ...

Matching PubMed Articles

Understanding Community Norms Surrounding Tobacco Sales.

In the US, denormalizing tobacco use is key to tobacco control; less attention has been paid to denormalizing tobacco sales. However, some localities have placed limits on the number and type of retai...

Antidepressant sales and the risk for alcohol-related and non-alcohol-related suicide in Finland-an individual-level population study.

A marked decline in suicide rates has co-occurred with increased antidepressant sales in several countries but the causal connection between the trends remains debated. Most previous studies have focu...

Retail Impact of Raising Tobacco Sales Age to 21 Years.

The majority of tobacco use emerges in individuals before they reach 21 years of age, and many adult distributors of tobacco to youths are young adults aged between 18 and 20 years. Raising the tobacc...

Occupational fatalities among driver/sales workers and truck drivers in the United States, 2003-2008.

This study provides a national profile of occupational fatalities among truck drivers and driver-sales workers.

Tricks of the Trade: Motivating Sales Agents to Con Older Adults.

Financial fraud is estimated to cost consumers approximately $50 billion annually. To examine how new hires are trained to engage in fraud, this study analyzed a sales training transcript from Allianc...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement